双歧三联活菌胶囊在感染幽门螺杆菌消化道疾病患者中的治疗作用分析.docVIP

双歧三联活菌胶囊在感染幽门螺杆菌消化道疾病患者中的治疗作用分析 　　摘要：目的 观察双歧三联活菌胶囊在感染幽门螺杆菌消化道疾病患者中的治疗效果。方法 选取2012年1月～2014年6月在我院进行诊断和治疗的幽门螺杆菌阳性的慢性胃炎和消化性溃疡患者80例，随机分为观察组与对照组，每组各40例，对照组给予雷贝拉唑三联疗法10d，观察组在给予雷贝拉唑三联疗法7d后，改为给予双歧三联活菌胶囊7d。停药1个月后比较两组患者幽门螺杆菌清除率及临床疗效。结果 观察组H.pylori根除率90% 显著高于对照组70% （P0.05） 。临床疗效评价：观察组总有效率达95%，对照组总有效率77.5%，差异显著（P0.05）。结论 在感染幽门螺杆菌消化道疾病患者中应用双歧三联活菌胶囊可提高H.pylori根除率，更有效缓解临床症状。 　　关键词：双歧三联活菌胶囊；慢性胃炎；消化性溃疡；幽门螺杆菌；感染 　　Abstract：Objective To observe the treatment effect of Bifid Triple Viable capsules used in patients with digestive tract disease who infected Helicobacte rpyloric. Methods 80 Helicobacter pylori positive chronic gastritis and peptic ulcer patients who were diagnosed and treated in our hospital from 2012 January to 2014 June were randomly divided into observation group and control group with 40 cases in each group.The control group was given Rabeprazole triple therapy for 10 days， while the observation group was given Rabeprazole triple therapy for 7 days，？then changed to a given Bifid Triple Viable capsule for 7 days. One month after Withdrawal Helicobacter pylori eradication rate and clinical efficacy were compared between the two groups.Results The H.pylori eradication？rate in the observation group was 90%， significantly higher than 70% in the control group （P0.05）.The total effective rate was 95% in the observation group， and 77.5% in the control group.The difference was statistically significant（P0.05）. Conclusion Bifid Triple Viable capsules can improve the eradication rate of H.pylori application，more effectively relieve the clinical symptoms of patients with digestive tract disease. 　　Key words：Bifid triple viable capsules；Chronic gastritis；Peptic ulcer；Helicobacter pylori；Infection 　　幽门螺旋杆菌（Helicobacter pylori，H.pylori）是存在于胃黏膜组织中的一种微需氧的革兰氏阴性菌，在我国感染率总体上仍然很高，成人中感染率达到40～60%[1]。H.pylori感染与上胃肠道疾病密切相关。由于H.pylori对抗生素耐药率的增加及根除治疗过程中不良反应的出现，导致标准三联疗法H.pylori 根除率逐渐下降。益生菌辅助治疗H.pylori感染已取得一些成果，其在提高H.pylori根除率、降低不良反应中的作用日益受到重视。在H.pylori根除治疗中何时加用益生菌、加用何种益生菌成为国内外研究的热点，本研究旨在观